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[57] ABSTRACT 
The invention relates to a novel method of administer 
ing aspirin to achieve improved delivery thereof. The 
invention further relates to novel dosage forms of neu 
tralized aspirin adapted for nasal administration, such as 
solutions, suspensions, gels and ointments. These dosage 
forms ?nd utility in the treatment of conditions known 
to respond to the administration of aspirin, particularly 
in the treatment of migraine and in the mitigation of 
cardiovascular damage resulting from heart attack. 
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NOVEL METHOD OF ADMINISTERING ASPIRIN 
AND DOSAGE FORMS CONTAINING SAME 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to a novel method of 
administering aspirin, and to novel dosage forms con 
taining same which are adapted for nasal administration. 
2. Background Art 
Aspirin is a well-known analgesic, antipyretic and 
anti-in?ammatory agent widely used in the treatment of 
pain, fever and in?ammation. It is particularly useful in 
the treatment of acute pain, such as post-operative pain. 
Aspirin has been used in the recent past in the treat 
ment of migraine, but with varying degrees of success. 
See, for example, Ross-Lee et al, Cephalalgia, Vol. 2, 
9-14 (1982) and other studies referred to therein. Ross 
Lee et al found that oral aspirin (900 mg) frequently 
relieved the pain of migraine attacks, particularly when 
combined with oral or intramuscular metoclopramide 
(10 mg). Further, those authors noted a correlation 
between better pain relief and higher aspirin and. salicyl 
ate plasma levels. Subsequently, Noda et al, J. Neurol. 
Neurosurg. Psychiatry, 48 (11), 1187 (1985) reported 
successful treatment of migraine attacks with 497 mg of 
intravenous aspirin (DL-lysine-acetylsalicylate). 
It is believed that aspirin can be successful in treating 
migraine for two reasons. When taken early in an at 
tack, aspirin may work by inhibiting platelet aggrega 
tion, which is thought to be the biochemical trigger of 
migraine attacks. When administered at a later stage, 
aspirin or the salicylate it releases may inhibit prosta 
glandin synthesis and thus help to relieve pain. Never 
theless, there is evidence that early treatment is associ 
ated with better relief. See Ross-Lee et al and Noda et 
al, supra. 
In the treatment of severe migraine, fast and reliable 
relief is of utmost importance. Unfortunately, it appears 
that aspirin is most effective and works most quickly 
when given intravenously. This route of administration 
obviously has its inherent drawbacks, including lack of 
patient acceptance for esthetic reasons and lack of con 
venience. For example, intravenous aspirin is typically 
administered by trained personnel in a hospital setting; 
it is not suitable for patient self-medication. Moreover, 
since aspirin is most efficacious when it is administered 
early in the migraine attack, immediate availability of 
treatment and ease of administration are especially im 
portant. 
Oral ingestion would be an ideal route of administra 
tion, but absorption from oral dosage forms is slower 
and more erratic; moreover, vomiting often accompa 
nies migraine, causing loss of part or all of the drug 
administered. Indeed, since oral aspirin is often irritat 
ing to the stomach, oral administration may even in 
crease the tendency toward vomiting. 
Rectal dosage forms of aspirin exist and might be 
useful in treating migraine, but would be impractical 
when diarrhea accompanies migraine attack. Moreover, 
rectal dosage forms suffer from lack of patient accep 
tance for esthetic reasons. 
It has recently been proposed that early administra 
tion of aspirin to heart attack victims would be very 
bene?cial in limiting damage to the cardiac muscle, due 
to aspirin’s prevention of platelet aggregation in the 
arteries. During the time immediately following a heart 
attack, when treatment is most critical, the patient may 
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be unconscious, making oral administration impossible. 
And, as in the case of migraine, oral absorption can be 
slow and erratic. On the other hand, intravenous admin 
istration may not be practical when it must be under 
taken by paramedics in a moving ambulance. And con 
tinuation of intravenous therapy during the weeks fol 
lowing a heart attack is impractical, since self-medica 
tion by this route would not be feasible. 
Thus, while aspirin remains the cornerstone of anal 
gesic therapy for many types of pain, its use in the treat 
ment of relatively severe pain, such as migraine head 
ache and postoperative pain, and its use in the early 
treatment of heart attack are fraught with difficulties. 
Migraine and post-operative pain may respond to oral 
aspirin, but the response is variable and unpredictable. 
Intravenous administration of neutralized aspirin, on the 
other hand, has been found to be both effective and 
reliable in treating‘ post-operative pain and in aborting 
migraine attacks, but this route of administration re 
quires a skilled operator and is. not suitable for patient 
self-medication. 
Previous studies by the present inventor and cowork 
ers have shown that selected drugs, e.g, propranolol, 
progesterone and estradiol, can be successfully adminis 
tered nasally. See, for example, Hussain et al, J. Pharm. 
Sci., 68, 1196 (1979); Hussain et al, J. Pharm. Sci, 69, 
1411 (1980); Hussain et al, J. Pharm. Sci, 70, 466 (1981); 
Hussain et al U.S. Pat. Nos. 4,284,648 and 4,315,925. 
Numerous other medications have thus far been admin 
istered nasally, with varying degrees of success. For an 
overview of the literature in this area, see “Historical 
Development of Transnasal Systemic Medications”, Y. 
W. Chien and S. F. Chang, in Transnasal Systemic Medi 
cations, ed. Y. W. Chien, Elsevier Science Publishers 
B.V., Amsterdam, 1985, l-99. However, the previously 
investigated drugs are structurally remote from aspirin, 
which has not been previously suggested for nasal ad 
ministration. 
SUMMARY OF THE INVENTION 
In view of the foregoing, it is apparent that a need 
exists for the improved delivery of aspirin, particularly 
to treat migraine and other types of severe pain and to 
mitigate the cardiovascular damage resulting from heart 
attack. Thus, it is an object of the present invention to 
provide novel dosage forms and a novel method of 
administering aspirin designed to provide enhanced 
bioavailability and minimized variations in blood levels 
as compared to oral aspirin, while at the same time 
providing relative ease of administration when com 
pared to intravenous injection. 
It is a further object of the present invention to pro 
vide a novel method and novel dosage forms containing 
aspirin useful in the treatment of migraine and other 
types of severe pain and in the mitigation of cardiovas 
cular damage caused by heart attack. 
Another object of the present invention is to provide 
a novel method of administering aspirin which rapidly 
produces the high blood concentrations of intact aspirin 
that are required to inhibit platelet aggregation and 
prostaglandin synthesis. 
Yet another object of the present invention is to pro 
vide a convenient, non-invasive method for the adminis 
tration of aspirin which avoids ?rst-pass metabolism, is 
safe and inexpensive, does not require a skilled operator 
and yet rapidly produces high blood concentrations of 
intact aspirin. 
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The foregoing objects are achieved by nasal adminis 
tration of neutralized aspirin. According to the inven 
tion, the neutralized aspirin is conveniently adminis 
tered via a novel nasal dosage form, i.e., an aqueous 
solution, suspension, ointment or gel adapted for nasal 
administration. 
BRIEF DESCRIPTION OF THE DRAWING 
The FIGURE of the drawing is a semi-logarithmic 
plot of mean plasma levels of salicylate in rats following 
intravenous(l)and intranasal (“administration of 2 mg 
doses 0 aspirin dissolved 0.1 mL of pH 7.4 phosphate 
buffer. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The term “aspirin” as used herein refers to 2 
(acetyloxy)benzoic acid, also known as salicylic acid 
acetate or acetylsalicylic acid, which has the structural 
formula 
COOH 
OOCCH3. 
Oral aspirin formulations typically contain from about 
300 to about 500 mg per dosage unit. Intravenous aspi 
rin has been formulated containing approximately 500 
mg aspirin per vial, the aspirin being used in the form of 
the amino acid salt, DL-lysine-acetylsalicylate. 
The term “neutralized aspirin” as used herein means 
acetylsalicylic acid in a water-solubilized salt form for 
mulated in neutral aqueous media. Such salt forms in 
clude water-soluble stable salts such as the amine salts, 
for example salts formed by aspirin with amines such as 
triethanolamine or triethylamine, as well as amino acid 
salts such as DL-lysine-acetylsalicylate, formulated in 
aqueous media at neutral pH (pH 7 to 8, approximately). 
The salts may be prepared by well-known methods and 
then dissolved in aqueous media appropriate for nasal 
administration and adjusted, if necessary, to neutral pH, 
the aqueous media being discussed in more detail here 
inbelow. However, it is not necessary to isolate the salt 
before preparing the nasal composition. In a presently 
preferred embodiment of the invention, an aqueous 
solution of the selected base is prepared and the selected 
dosage of aspirin is simply dissolved in an appropriate 
volume of the aqueous alkaline solution. Thus, for ex 
ample, a 7% solution of triethanolamine in water is 
prepared. Then, to prepare a unit dose for nasal admin 
istration, 300 mg of aspirin are dissolved in 4 mL of the 
triethanolamine solution. Neutralized aspirin may be 
similarly prepared, for example, from diethylamine, 
phosphate buffer or acetate buffer, the solution being 
adjusted as necessary to about neutral to slightly alka 
line pH (7 to 8). 
In accord with the present invention, it has now been 
found that aspirin can be very efficiently delivered to 
the systemic circulation via nasal administration. The 
following study was undertaken to examine the bi 
oavailability of aspirin from nasal solution as compared 
to intravenous administration. 
Plasma levels of salicylates were studied in rats fol 
lowing intravenous and intranasal administration of 2 
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mg doses of aspirin dissolved in 0.1 mL of pH 7.4 phos 
phate buffer. 
Male Sprague-Dawley rats, each weighing about 300 
g, were used without fasting. For nasal administration, 
the surgical operation was carried out on the rats as 
described before [Hussain et al, J. Pharm. Sci, 69. 1411 
(1980)] after anesthetizing with pentobarbital sodium 
(50 mg/kg). The end of the tube which leads from the 
esophagus to the nasal cavity was closed. The neutral 
ized aspirin solution was administered to the nasal cav 
ity through the nostrils by means of a micropipet and 
the nostrils were closed with adhesive agent. For intra 
venous administration, the rats were anesthetized and 
the neutralized aspirin solution was injected through 
the femoral vein. 
After the administration of the drug, 0.4 mL of blood 
was sampled periodically from the femoral aorta. The 
concentrations of - salicylates in the blood specimens 
were determined using a speci?c HPLC assay. The 
results, depicted in the FIGURE, demonstrate that 
aspirin was rapidly absorbed by rats following intrana 
sal administration in accord with the present invention. 
Aspirin can‘be conveniently administered nasally by 
formulating it into a nasal dosage form comprising the 
selected form of neutralized aspirin and a nontoxic 
pharmaceutically acceptable nasal carrier therefor. 
Suitable nontoxic pharmaceutically acceptable nasal 
carriers for use in the compositions of the present inven 
tion will be apparent to those skilled in the art of nasal 
pharmaceutical formulations. For those not skilled in 
the art, reference is made to the text entitled “REM 
INGTON’S PHARMACEUTICAL SCIENCES”, 
17th edition, 1985, as well as to the many recent publica 
tions on nasal drug delivery, including Hussain et al 
U.S. Pat. Nos. 4,284,648 and 4,315,925, and Hussain 
U.S. Pat. Nos. 4,428,883 and 4,464,378. Obviously, the 
choice of suitable carriers will depend on the exact 
nature of the particular nasal dosage form desired, e.g., 
whether the active ingredient is to be formulated into a 
nasal solution (for use as drops or as a spray), a nasal 
suspension, a nasal ointment or cream or a nasal gel. 
Preferred nasal dosage forms are solutions, suspensions 
and gels, which contain a major amount of water (pref 
erably puri?ed water) in addition to the active ingredi 
ent. Minor amounts of other ingredients such as pH 
adjusters (e.g., a base such as NaOH), emulsi?ers or 
dispersing agents (e. g., polyoxyethylene 20 sorbitan 
monooleate), buffering agents, preservatives, wetting 
agents and jelling agents (e.g., methylcellulose) may 
also be present. Sustained release compositions, such as 
sustained release ointments and gels, are of particular 
interest. 
The method and compositions of the present inven 
tion may be used in the treatment of any condition for 
which aspirin can be used, but are especially of interest 
for the treatment for migraine and for the mitigation of 
cardiovascular damage resulting from heart attack. 
Examples of the preparation of typical nasal composi 
tions are set forth below. However, it is to be under 
stood that these examples are given by way of illustra 
tion only and are not to be construed as limiting the 
invention either in spirit or in scope as many modi?ca 
tions both in materials and in methods will be apparent 
to those skilled in the art. 
EXAMPLE 1 
7.5 Grams of aspirin are combined with 90 mL of a 
7% solution of triethanolamine in water. The pH is 
4,885,287 
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adjusted to about pH 8, the solution is made isotonic 
with sodium chloride solution and the total volume is 
brought to 100 mL. The composition contains 300 mg 
of aspirin per 4 mL. 
EXAMPLE 2 
Isotonic saline (500 mL) is heated to 80° C. and 
methyl cellulose (2 g) is added, with stirring. The resul 
tant mixture is allowed to stand at room temperature for 
2 hours. Then, 75 grams of aspirin in 450 mL of 7% 
triethanolamine in isotonic saline is added and the pH is 
adjusted to about pH 8. A further quantity of isotonic 
saline suf?cient to bring the total volume to 1 liter is 
added to the gel and thoroughly mixed. The gel con 
tains 300 mg of aspirin per 4 mL. 
Naturally, the therapeutic dosage range for nasal 
administration of the compositions of the present inven 
tion will vary with the size of the patient and the condi 
tion for which the composition is administered. More 
over, the quantity of nasal dosage form needed to de 
liver the desired dose will depend on the concentration 
of aspirin in the composition. A typical unit dose for the 
treatment of migraine or heart attack is 300 mg every 6 
hours. 
While the invention has been described in terms of 
various preferred embodiments, the skilled artisan will 
appreciate that various modi?cations, substitutions, 
omissions and additions may be made without departing 
from the spirit thereof. Accordingly, it is intended that 
the scope of the present invention be limited solely by 
the scope of the following claims. 
What is claimed is: 
1. A method of inhibiting platelet aggregation and/ or 
prostaglandin synthesis in a mammal in need of such 
treatment which comprises nasally administering 
thereto an effective platelet aggregation-inhibiting and 
/or prostaglandin synthesis-inhibiting amount of neu 
tralized aspirin. 
2. A method according to claim 1 which comprises 
nasally administering to said mammal a pharmaceuti 
cally acceptable nasal dosage form comprising an effec 
tive platelet aggregation-inhibiting and/or prostaglan 
din synthesis-inhibiting amount of neutralized aspirin 
and a nontoxic pharmaceutically acceptable nasal car 
rier therefor. 
3. A method according to claim 2, wherein said nasal 
dosage form is a nasal solution, a nasal suspension, a 
nasal ointment or a nasal gel. 
4. A method according to claim 2, wherein said dos 
age form is a sustained release nasal dosage form. 
5. A method according to claim 2, wherein said dos 
age form is a sustained release nasal gel. 
6. A method according to claim 2, wherein said dos 
age form is isotonic. 
7. A method for the treatment of migraine which 
comprises nasallyvadministering to a patient in need of 
such treatment an effective anti-migraine amount of 
neutralized aspirin. 
8. A method according to claim 7 which comprises 
nasally administering to said patient a pharmaceutically 
acceptable nasal dosage form comprising an effective 
anti-migraine amount of neutralized aspirin and a non 
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toxic pharmaceutically acceptable nasal carrier there 
for. 
9. A method according to claim 8, wherein said nasal 
dosage form is a nasal solution, a nasal suspension, a 
nasal ointment or a nasal gel. 
10. A method according to claim 8, wherein said 
dosage form is a sustained release nasal dosage form. 
11. A method according to claim 8, wherein said 
dosage form is a sustained release nasal gel. 
12. A method according to claim 8, wherein said 
dosage form is isotonic. 
13. A method for mitigating cardiovascular damage 
resulting from heart attack which comprises nasally 
administering to a heart attack victim an effective 
amount of neutralized aspirin. 
14. A method according to claim 13 which comprises 
administering to said heart attack victim a pharmaceuti 
cally acceptable nasal dosage form comprising an effec 
tive amount of neutralized aspirin and a nontoxic phar 
maceutically acceptable nasal carrier therefor. 
15. A method according to claim 14, wherein said 
nasal dosage form is a nasal solution, a nasal suspension, 
a nasal ointment or a nasal gel. 
16. A method according to claim 14, wherein said 
dosage form is a sustained release nasal dosage form. 
17. A method according to claim 14, wherein said 
dosage form is a sustained release nasal gel. 
18. A method according to claim 14, wherein said 
dosage form is isotonic. 
19. A pharmaceutically acceptable nasal composition, 
in dosage unit form, for nasal administration to inhibit 
platelet aggregation and/ or prostaglandin synthesis in a 
mammal, said composition comprising, per nasal dosage 
unit, a systemically effective platelet aggregation-inhib 
iting and/or prostaglandin synthesis-inhibiting amount 
of neutralized aspirin and a nontoxic pharmaceutically 
acceptable carrier therefor, said composition compris 
ing a nasal ointment or a nasal gel. 
20. A pharmaceutically acceptable nasal composition, 
in dosage unit form, for nasal administration in the treat 
ment of migraine, said composition comprising, per 
nasal dosage unit, a systemically effective anti-migraine 
amount of neutralized aspirin and a nontoxic pharma 
ceutically acceptable carrier therefor, said composition 
comprising a nasal ointment or a nasal gel. 
21. A pharmaceutically acceptable nasal composition, 
in dosage unit form, for nasal administration in the miti 
gation of cardiovascular damage resulting from heart 
attack, said composition comprising, per nasal dosage 
unit, a systemically effective amount of neutralized 
aspirin and a nontoxic pharmaceutically acceptable 
carrier therefor, said composition comprising a nasal 
ointment or a nasal gel. 
22. A composition according to claim 19, said compo 
sition being adapted for sustained release to the nasal 
mucosa. 
23. A composition according to claim 20, said compo 
sition being adapted for sustained release to the nasal 
mucosa. 
24. A composition according to claim 21, said compo 
sition being adapted for sustained release to the nasal 
mucosa. 
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